Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Eli Kalif

    - PMLiVE

    FDA approves Teva’s Ajovy to prevent episodic migraine in paediatric patients

    One in ten children and adolescents in the US are affected by the neurological condition

    - PMLiVE

    Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

    About ten million people worldwide are affected by inflammatory bowel disease

    - PMLiVE

    AbbVie’s Allergan reaches proposed $2.37bn agreement to settle US opioid lawsuits

    Together with Teva Pharmaceutical’s proposed $4.25bn deal, the total settlement deal could be worth $6.6bn

    - PMLiVE

    Teva reaches proposed $4.25bn agreement to settle US opioid lawsuits

    The figure includes the supply of up to $1.2bn of Teva’s Narcan, a life-saving medication which can reverse an overdose from opioids

    - PMLiVE

    Eli Lilly focuses on 2022 launches as revenues climb by 18%

    Revenues in the third quarter of 2021 were driven by volume growth in new medicines, but earnings per share were a fraction below analysts’ predictions

    - PMLiVE

    Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

    The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

    - PMLiVE

    AZ is expecting late-stage COVID-19 vaccine data this year

    Company reiterated timeline in third quarter results

    - PMLiVE

    Keytruda growth helps Merck to offset COVID-19 impact in Q3

    Profits beat expectations in the third quarter of 2020

    - PMLiVE

    Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

    Data monitoring committee has not yet conducted any interim efficacy analysis of the shot

    - PMLiVE

    Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

    Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

    - PMLiVE

    Novartis weathers the COVID-19 storm in Q3, lifts outlook

    Core operating income increased by 11%, profits from net income drop

    - PMLiVE

    Purdue to pay over $8bn to settle opioid-related criminal claims

    Claims relate to Purdue's involvement in fuelling the opioid addiction crisis

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links